Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nicergoline→

Nicergoline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
27848-84-6
Molecular formula
C24H26BrN3O3
Molecular weight
484.39 g/mol
Drug class
Ergot-derived alpha-1 adrenergic receptor antagonistperipheral and cerebral vasodilator
Mechanism of action
Antagonises alpha-1 adrenergic receptors on vascular smooth muscle, reducing catecholamine-mediated vasoconstriction and increasing blood flow. It also has effects on cerebral metabolism and platelet aggregation described in pharmacology studies.
Indications / reported uses
  • Historically used in selected countries for peripheral vascular disorders and cognitive symptoms associated with cerebrovascular disease; current indications and availability are restricted or vary by jurisdiction.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/34040 · https://pubmed.ncbi.nlm.nih.gov/?term=nicergoline+pharmacology+alpha1+adrenoceptor · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Ergot-derived alpha-1 adrenergic receptor antagonist; peripheral and cerebral vasodilator

Mechanism of action

Antagonises alpha-1 adrenergic receptors on vascular smooth muscle, reducing catecholamine-mediated vasoconstriction and increasing blood flow. It also has effects on cerebral metabolism and platelet aggregation described in pharmacology studies.

General use cases

  • Historically used in selected countries for peripheral vascular disorders and cognitive symptoms associated with cerebrovascular disease; current indications and availability are restricted or vary by jurisdiction.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Nicergoline Environmental Risk Assessment (ERA) (the Nicergoline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.